Fast Money Traders Discuss Merck, Garmin And Sarepta Therapeutics

On CNBC's Fast Money, Stephanie Link said that Merck & Co., Inc. MRK posted a fine quarter although the company missed revenue expectations and it narrowed its full year forecast. The stock dropped 2.01 percent on Monday and Link thinks that profit taking is the reason for a decline. Given the run that Merck had she wouldn't chase the stock. Jim Lebenthal likes Garmin Ltd. GRMN, which traded 2.44 percent higher on an upgrade by Goldman Sachs. He thinks that placing less emphasis on personal navigation and stepping into original equipment manufacturing for automobile and other sectors is good for the company. Joe Terranova wouldn't buy Sarepta Therapeutics Inc SRPT after it dropped 32.47 percent on Monday. He added that it looks like its new drug application will be delayed for mid 2015.